Pieris are easy-to-grow and cold-hardy evergreen shrubs with dark fingered foliage that is attractive all year round. This plant (also known as the andromeda bush or the lily-of-the-valley bush) ...

Shares drop after the company announces the pricing details of a common stock offering. However, investors learned today that the company succeeded in selling 5.5 million shares to the public, but the ...

My first spring catalog has come. The excitement at our house is at a winter high — thinking of all of the green that comes with spring and the opportunities to add to my landscape. I have marked ...

The signing of a lucrative collaboration deal causes the share price to jump. This deal provides Pieris with an up-front payment of $30 million and the ability to earn up to $1.2 billion in milestone ...

PierisPharmaceuticals’ PIRS shares plunged almost 70% on Jun 21 and 15% on Jun 22, as its partner AstraZeneca AZN decided to discontinue and cease dosing in the ongoing mid-stage study of elarekibep.

Pieris Pharmaceuticals is trimming the fat, putting its lead immuno-oncology asset on the chopping block to make more room for its AstraZeneca partnership. With the readout for the ...

Pieris received a grant of $17 million from the Bavarian Ministry of Economic Affairs for a drug to treat lung scarring in COVID sufferers. Shares of Pieris Pharmaceuticals (PIRS) jumped on Friday ...

BOSTON, MA / ACCESSWIRE / November 2, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin ® ...

US biotech Pieris Pharmaceuticals has begun a collaboration and supply agreement with Eli Lilly, trialling its cancer drug PRS-343 in combination with the big pharma’s Cyramza (ramucirumab). PRS-343 ...

FREISING-WEIHENSTEPHAN, Germany, January 4 /PRNewswire/ -- Pieris AG today announced the appointment of Stephen S. Yoder as CEO with immediate effect. Mr. Yoder takes over the position from interim ...

Shares of Pieris Pharmaceuticals Inc. rocketed 57.3% on massive volume in afternoon trading Tuesday, after the Boston-based biotechnology company announced a respiratory and ophthalmology ...